• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

NeoStem Spotlights Projected Multibillion-Dollar Adult Stem Cell Therapeutics Market in Latest Investor Video

Posted on: Thursday, 18 October 2007, 06:00 CDT

NeoStem, Inc. (AMEX:NBS), a leading-edge healthcare company which seeks to capitalize on existing applications and anticipated breakthroughs in the burgeoning field of stem cell therapeutics, has released a new investor video detailing the promise of the hundreds of adult stem cell clinical trials currently underway to treat many of the world's most intractable diseases. Industry analysts predict that the adult stem cell industry will generate approximately $8.5 billion by 2016, should these therapies come to market as and when expected.

Robin Smith, MD, MBA, Chief Executive Officer of NeoStem, also details why the Company's services should play a key role as the field of Regenerative Medicine fulfills the promise that many medical and scientific professionals anticipate.

"In the United States alone, there are nearly 700 ongoing studies currently underway to develop medical therapies based on adult stem cells, with nearly 200 of them focused on autologous applications," said Dr. Smith during the video. "NeoStem believes there will be an overall growth in the adult stem cell industry, and it will be well positioned to capitalize on this growth."

NeoStem believes its first-to-market competitive advantage should uniquely position the Company to capitalize on the hundreds of therapeutic stem cell-based research programs currently underway. Should these stem cell-based therapies become available, as so many expect, NeoStem clients may be among the first to benefit from the therapeutic progress that many trials have demonstrated for treatment of cancer, heart disease, multiple sclerosis and lupus, among other debilitating conditions.

"As education about these issues spreads, we believe autologous adult stem cell banking will be a form of personal bio-insurance that will continue to grow," said Dr. Smith during the video.

To view "The Promise of Stem Cells" investor video, please visit http://www.trilogy-capital.com/tcp/neostem/.

About NeoStem, Inc.

NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the national trend toward protecting one's future health.

The Company's business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.

For more information, please visit: www.neostem.com.

For other information and resources about the Company, visit www.CFSG1.com or www.trilogy-capital.com/tcp/neostem/quote.html.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.

Source: Business Wire

More News in this Category